SOURCE: MicroPhage, Inc.

MicroPhage, Inc.

May 19, 2011 11:37 ET

MicroPhage KeyPath™ AST Clinical Trial Data Presented at the Upcoming ASM

LONGMONT, CO--(Marketwire - May 19, 2011) - MicroPhage, Inc., developers of quick easy-to-use diagnostic products for bacterial identification, antibiotic susceptibility and resistance testing, announced today that lead investigators in its clinical trial of the KeyPath™ MRSA/MSSA Blood Culture Test will present their data at the American Society of Microbiology meeting this weekend in New Orleans. Tom Kirn, MD, Assistant Professor of Pathology & Laboratory Medicine at the UMDNJ-Robert Wood Johnson Medical School, will present the data during a poster session on Monday afternoon, May 23, from 1:00 to 2:45 PM CST (poster 1607).

The clinical trial was conducted at four prestigious medical centers including Duke University Medical Center, Northwestern University, Denver Health and UMDNJ-Robert Wood Johnson Medical School. The data generated during the clinical trial provided the basis for the US FDA to grant marketing clearance for the test on May 6th. The test was 98.9 percent accurate (178/180) for MRSA identification and 99.4 percent accurate (153/154) in determining MSSA within the organisms identified as S. aureus.

Also, during the same poster session investigational data on the use of a similar MicroPhage product in pediatric populations will also be presented by Karin L. McGowan, Ph.D., F(AAM), M.S., SM(NRCM), Director of the Microbiology lab and Kaeda Ota, MD, Assistant Director of the Microbiology Lab at the Children's Hospital of Philadelphia.

The KeyPath™ MRSA/MSSA Blood Culture Test is the first and only same-day antibiotic susceptibility test that is able to quickly diagnose and distinguish whether the bacteria are methicillin resistant (MRSA) or methicillin susceptible (MSSA).

About MicroPhage
Based in Longmont, Colorado, privately held MicroPhage, Inc. develops accelerated, easy-to-use diagnostic products for bacterial identification and antibiotic susceptibility/resistance testing. Using its proprietary Bacteriophage Amplification Test (BAT™) platform, the Company has developed patented processes that provide a platform for quick, easy-to-use, inexpensive diagnostic tests. The MicroPhage BAT™ test platform does not require any instrumentation and is simple to operate, enabling microbiology testing outside of traditional laboratory settings.

Contact Information